ArticleMaterials today. Bio2025
Reshaping tumor immune microenvironment through ROS-responsive prodrug polyplexes via synergistic effect of CRISPRi system and epigenetic inhibitor for breast cancer therapy.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Genetic Interruption of PD-1/PD-L1 as an Alternative Means for Immune Checkpoint Blockade in Cancer: A Review.Pharmaceutics · 2026Review
- From LNPs to hybrid nanocarriers: development, challenges and redesign of non-viral gene delivery.Journal of nanobiotechnology · 2026Review
- Engineered lipid hybrid nanoparticles for targeted delivery of SH2 superbinder and breast cancer therapy.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Engagement of programmed death-ligand 1 (PD-L1) on tumor cells with its receptor PD-1 on immune cells can transmit an inhibitory signal to induce immune evasion. Although the immune checkpoint inhibitor PD-L1 antibody has shown antitumor capability in clinical treatment, its wide clinical application still faces several side effects and individual selectivity. In our research, we utilized the Clustered Regularly Interspaced Short Palindromic Repeats interference (CRISPRi) system to suppress PD-L1 expression on breast cancer cells (4T1) and combined it with epigenetic inhibitor azacytidine (AZA) for enhanced cancer immunotherapy. Reactive oxygen species (ROS)-responsive poly(β-amino ester) (PBAE)-S-AZA cationic polymeric prodrug was fabricated, which could complex with CRISPRi plasmids to form the composite polyplexes via electrostatic interaction. The composite polyplexes could be taken up by tumor cells with high efficiency, followed by plasmid release with the cooperation of PBAE. The CRISPRi plasmids could lead to PD-L1 downregulation in tumor cells, leading to obvious relief of immune checkpoint blockade. In the meantime, the epigenetic inhibitor AZA was also released from the polyplexes due to the high intracellular ROS level, thereby enhancing the efficacy of immunotherapy via elevating MHC class I expression, enhancing antigen presentation, and inducing dendritic cell (DC) maturation. The ROS-responsive polyplexes helped to realize the combination of genome editing, immunotherapy, and epigenetic regulation. It will provide an effective platform for promoting antitumor treatment and precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.